Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III trial of Heartcel in patients with cardiomyopathy

Trial Profile

A phase III trial of Heartcel in patients with cardiomyopathy

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CLXR 001 (Primary)
  • Indications Cardiomyopathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jul 2020 Status changed from recruiting to suspended, according to a Celixir meida release.
    • 06 Jul 2020 According to a Celixir meida release, recruitment in this study is scheduled to recommence under a new CTA in Q3 2020 and the study is expected to complete in 2021.
    • 06 Jul 2020 According to a Celixir meida release, after consultation with the Medicines and Healthcare products Regulatory Agency (MHRA), the company has decided to suspend this study due to covid-19 pandemic. The company has decided to replace the current clinical trial application (CTA) with a revised protocol.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top